可选产品分析
经您允许，我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Accelerated margin expansion through CenterWell clinical services and aggressive Medicare Advantage repricing.
Insurance segment operating margin falling below 1.20% in FY2026 or FY2027,.
We rate Humana Sell with a Fair value of $264.45, representing 31.91% downside from the report-date price of $388.36 on October 2, 2026, as elevated senior medical costs and regulatory tightening leave market expectations well ahead of underlying underwriting recovery.4
We rate Humana Sell. For an ordinary investor, this rating means Humana shares are substantially overvalued relative to their fundamental earnings power, and investors should avoid opening new positions or reduce existing equity exposure.
The report was prepared at a price of $388.36 on October 2, 2026. That price sits 46.9% above our Fair value of $264.45, representing an implied return of -31.91%. Even under optimistic recovery assumptions, the report-date price remains well above our Potential value of $334.97.4
The strongest operational driver supporting Humana's core business is its CenterWell healthcare services platform. By delivering senior primary care, home health, and pharmacy services at a 5.96% operating margin ($1.34 billion operating profit on $22.47 billion revenue in FY2025,), CenterWell captures profitable provider-side economics and improves clinical coordination for senior patients. As CenterWell matures its clinics and expands care to external health plans, high-margin healthcare services generate steady operating cash flow that cushions insurance underwriting swings and allows long-term diluted EPS to normalize toward consensus estimates of $16.57 by FY2027.17
CenterWell delivers high-margin primary care, home health, and pharmacy services, generating $1.34B in operating profit with a 5.96% margin in FY2025, offering structural earnings defense against underwriting volatility.7
Humana is executing disciplined Medicare Advantage contract repricing, exiting unprofitable counties, and curbing medical costs to restore segment margins from the 1.34% FY2025 trough, supporting consensus FY2027 EPS recovery toward $16.57.17
The steady expansion of the U.S. population aged 65 and older drives persistent baseline demand for Medicare Advantage plans and senior-focused clinical primary care coordination.7
We rate Humana Sell because the shares trade at an unsustainable 46.9% premium to our Fair value of $264.45 while severe Medicare Advantage medical cost inflation and elevated regulatory scrutiny constrain underwriting profitability and cash flow generation,.4
HUMANA INC provides centralized intercompany services to each of its health plans and to its business segments from its headquarters and service centers. These services include management information systems, product development and administration, finance, human resources, accounting, law, public relations, marketing, insurance, purchasing, risk management, internal audit, actuarial, underwriting, claims processing, billing/enrollment, and customer service. The products offered by its CenterWell segment are key to its integrated care delivery model. This segment includes its pharmacy solutions, primary care, and home solutions operations. The CenterWell segment includes its pharmacy solutions, primary care, and home solutions operations.
Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.
A compound stress scenario combining sustained elevated Medicare Advantage medical utilization, adverse CMS risk-adjustment coding changes, and Star rating bonus penalties severely challenges Humana's financial structure. In FY2025, Insurance operating income contracted to $1.66B on $124.56B revenue,, suppressing consolidated operating cash flow to $921M and free cash flow to $375M. Under sustained regulatory reimbursement tightening and elevated senior inpatient care, segment operating margins would remain trapped near 1.20%, preventing consensus diluted EPS from recovering toward $16.57 by FY2027 and pinning earnings near the analyst trough of $10.39. In this environment, total debt of $12.94B ($14.74B as of October 2026) with annual interest charges of $631M creates substantial balance sheet drag, while a 200 bps increase in cost of equity to 10.54% drives forward earnings valuation down to $107.85.
In FY2025, elevated utilization compressed Insurance operating income to $1.66B on $124.56B revenue (1.34% margin),. If senior utilization surges further and Star rating cuts reduce CMS quality bonus payments, segment margin falling below 1.2% would abort earnings recovery and keep EPS near the analyst low of $10.39.17
可能削弱我们投资逻辑的五项变化。
Indicates senior medical utilization or Star rating quality penalties are overwhelming contract repricing, invalidating underwriting margin restoration.
当前：1.34% in FY2025
触发警报：Below 1.20%
Humana commands a Narrow economic moat grounded in scale advantages within Medicare Advantage administration and switching costs tied to its dedicated senior care delivery network. With $124.56B in Insurance segment revenue in FY2025, Humana represents the second-largest Medicare Advantage platform in the United States. This enrollment density provides negotiated provider fee concessions, optimized claims processing infrastructure, and an established distribution footprint that cannot be easily replicated by regional entrants.
However, the durability of this moat has narrowed significantly due to heightened regulatory scrutiny and medical loss ratio inflation. When senior medical utilization escalated throughout FY2024 and FY2025, Insurance operating income contracted to $1.66B (a 1.34% operating margin), down from consolidated operating profits of $4.01B in FY2023. In contrast to diversified peers such as Elevance Health (4.56% operating margin) and UnitedHealth Group (7.13% operating margin), Humana derives 96.1% of revenues from government health insurance, leaving its competitive advantage acutely sensitive to CMS benchmark rate updates.
The CenterWell clinical services segment serves as a vital structural defense, generating $1.34B in operating profit on $22.47B in revenue in FY2025 (5.96% margin),. CenterWell integrates primary care clinics, home health, and specialty pharmacy to capture provider-side economics, enhance clinical outcomes, and lock in patient retention. Nevertheless, because $17.37B of CenterWell revenue represents internal intersegment eliminations against health plan members, its standalone moat protection remains tethered to the underlying Medicare Advantage enrollment base.
Humana's current return on invested capital of 6.31% sits 137 bps below its computed weighted average cost of capital of 7.68%. While consolidated operating income averaged $3.65B annually between FY2021 and FY2023, the surge in senior medical utilization compressed FY2025 operating income to $2.70B, temporarily eliminating economic profit creation until Medicare Advantage contract repricing and benefit design adjustments take hold.26
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($264.45). Each row and column shows what Fair value becomes when one assumption moves.
A free-cash-flow drop test is not available in this run; use the discount-rate and terminal-growth grid as the primary valuation pressure test.
The Base scenario models a multi-year operational turnaround where disciplined Medicare Advantage contract repricing and administrative cost controls lift Insurance segment operating margins toward mid-cycle norms. The Base target of $264.45 carries a 55.0% probability, implying an expected return of -31.9% from $388.36 (as of 2026-10-02). Confirmation requires steady progression in segment margins across quarterly checkpoints, while failure to restore underwriting profitability by FY2027 would disconfirm this trajectory.
An operational beat driven by faster underwriting margin restoration would begin closing the gap between $388.36 and $264.45, signaling that contract repricing is successfully overcoming healthcare cost pressures.
In-line operational results confirm that underwriting recovery proceeds slowly and share pricing at $388.36 continues to trade at a substantial premium above $264.45.
Earnings misses confirm that structural headwinds in government programs are impairing underwriting margins, reinforcing downside risk toward $264.45.
Earnings quality exhibits substantial divergence between reported GAAP net income and underlying operating cash flow, influenced by working-capital volatility, CMS risk-adjustment settlement cycles, and claims reserve timing. While first-half disclosures demonstrated cash flow recovery following working-capital compression in the prior fiscal period, multi-year operating cash conversion remains volatile due to Medicare Advantage claims seasonality. High reliance on captive clinical earnings from the healthcare services segment partially cushions consolidated operating income, but regulatory statutory capital reserve requirements and substantial balance-sheet leverage restrict discretionary cash generation.
Underwriting profitability determines whether operating income can normalize toward historical averages or whether contractual margins remain permanently impaired by medical utilization.
Operating cash flow experienced severe cyclical compression in FY2025, falling 69.0% to $921M from $2.97B in FY2024 and $3.98B in FY2023. This collapse reflected senior medical cost inflation and claims settlement timing that reduced net income to $1.19B. Free cash flow correspondingly contracted to $375M after deducting capital expenditures of $546M. Although first-half FY2026 disclosures indicate an operational rebound with 6-month YTD operating cash flow reaching $3.22B, historical cash generation demonstrates extreme vulnerability to Medicare Advantage medical loss ratio cycles.56
Humana's capital allocation has shifted toward liquidity preservation in response to underwriting margin compression. Consolidated total debt stood at $12.94B at year-end FY2025 ($14.74B as of October 2026) against cash and equivalents of $4.20B, resulting in a capital structure debt weight of 24.02%. Annual interest expense was $631M in FY2025, consuming 23.3% of ($2.70B). In response, Humana curtailed share buybacks to $151M in FY2025 from $817M in FY2024 and $1.57B in FY2023, while holding dividend distributions steady at $430M. remained lean at $546M in FY2025 (0.42% of ), but discretionary capital returns will remain restricted until normalizes.
ROIC has deteriorated from historical double-digit averages as operating income dropped from $4.01B in FY2023 to $2.70B in FY2025 while invested capital rose to $30.03B. Humana is currently failing to earn its cost of capital, and ROIC cannot recover until Insurance underwriting margins return toward historical 3.0%-3.5% norms.
ROIC of 6.31% sits 137 bps below the computed WACC of 7.68%.
Operating cash flow fell to $921M in FY2025 from $2.97B in FY2024, compressing free cash flow to $375M.
| 营业收入 | US$129,664,000,000 |
|---|---|
| 营业成本 | US$110,812,000,000 |
| 毛利 | US$18,852,000,000 |
| 营业费用 | US$16,148,000,000 |
| 营业利润 | US$2,704,000,000 |
| 营业外项目及税项 | -US$1,516,000,000 |
| 净利润 | US$1,188,000,000 |
| 总资产 | US$48,909,000,000 |
|---|---|
| 现金 | US$4,200,000,000 |
| 流动资产 | US$32,733,000,000 |
| 总负债 | US$31,172,000,000 |
| 流动负债 | US$16,346,000,000 |
| 股东权益 | US$17,737,000,000 |
| 净利润 | US$1,188,000,000 |
|---|---|
| 经营现金流入 | US$2,127,000,000 |
| 折旧与摊销 | US$698,000,000 |
| 股份支付 | US$241,000,000 |
| 经营现金流 | US$921,000,000 |
| 经营现金流出 | US$1,206,000,000 |
| 可用现金 | US$5,415,000,000 |
| 期初现金 | US$2,221,000,000 |
| 投资现金流入 | US$2,273,000,000 |
| 融资现金流出 | US$1,215,000,000 |
| 净债务发行 | US$431,000,000 |
| 股份回购 | US$151,000,000 |
| 已付股息 | US$430,000,000 |
| 其他融资活动 | US$1,065,000,000 |
| 期末现金 | US$4,200,000,000 |
| 投资现金流 | US$2,273,000,000 |
| 融资现金流 | -US$1,215,000,000 |
2026-10-02分析所采用的时点财务数据。
| 期间 | 营业收入 | EBITDA | 净利润 | 经营现金流 | 自由现金流 | 资本支出 | 折旧与摊销 | 股份支付 | 股份回购 | 已付股息 | 净债务发行 | 投资现金流 | 融资现金流 | 期初现金 | 期末现金 | 现金与投资 | 总债务 | 营业利润率 | ROIC | WACC | ROIC−WACC利差 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | US$543.8亿 | US$22.1亿 | US$6.1亿 | US$19.4亿 | US$14.1亿 | US$5.3亿 | US$3.9亿 | US$1.2亿 | US$1亿 | US$1.8亿 | — | -US$13.6亿 | US$7.3亿 | — | US$38.8亿 | US$114.7亿 | US$40.9亿 | 3.2% | — | 5.7% | — |
| 2017-12-31 | US$537.7亿 | -US$9.4亿 | US$24.5亿 | US$40.5亿 | US$35.3亿 | US$5.2亿 | US$4.1亿 | US$1.6亿 | US$33.7亿 | US$2.2亿 | — | -US$29.4亿 | -US$9.5亿 | US$38.8亿 | US$40.4亿 | US$136亿 | US$49.2亿 | 7.9% | — | 5.7% | — |
| 2018-12-31 | US$569.1亿 | US$28.3亿 | US$16.8亿 | US$21.7亿 | US$15.6亿 | US$6.1亿 | US$4.4亿 | US$1.4亿 | US$10.9亿 | US$2.7亿 | — | -US$30.9亿 | -US$7.9亿 | US$40.4亿 | US$23.4亿 | US$123.7亿 | US$60.7亿 | 5.4% | — | 6.4% | — |
| 2019-12-31 | US$648.9亿 | US$42.9亿 | US$27.1亿 | US$52.8亿 | US$45.5亿 | US$7.4亿 | US$5.8亿 | US$1.6亿 | US$10.7亿 | US$2.9亿 | — | -US$12.8亿 | -US$23亿 | US$23.4亿 | US$40.5亿 | US$150.3亿 | US$61.1亿 | 4.9% | — | 5.3% | — |
| 2020-12-31 | US$771.6亿 | US$55.7亿 | US$33.7亿 | US$56.4亿 | US$46.8亿 | US$9.6亿 | US$6.2亿 | US$1.8亿 | US$18.2亿 | US$3.2亿 | — | -US$30.7亿 | -US$19.6亿 | US$40.5亿 | US$46.7亿 | US$172.3亿 | US$71.4亿 | 6.5% | — | 4.2% | — |
| 2021-12-31 | US$830.6亿 | US$44.6亿 | US$29.3亿 | US$22.6亿 | US$9.2亿 | US$13.4亿 | US$6亿 | US$1.8亿 | US$7900万 | US$9000万 | — | -US$65.6亿 | US$30.2亿 | US$46.7亿 | US$33.9亿 | US$165.9亿 | US$132.3亿 | 3.8% | — | 4.6% | — |
| 2022-12-31 | US$928.7亿 | US$48.1亿 | US$28.1亿 | US$45.9亿 | US$34.5亿 | US$11.4亿 | US$7.1亿 | US$2.2亿 | US$21亿 | US$9800万 | -US$13.9亿 | -US$10.1亿 | -US$19.1亿 | US$33.9亿 | US$50.6亿 | US$189.4亿 | US$117.5亿 | 4.1% | — | 6.6% | — |
| 2023-12-31 | US$1063.7亿 | US$47.3亿 | US$24.9亿 | US$39.8亿 | US$29.8亿 | US$10亿 | US$7.8亿 | US$1.8亿 | US$15.7亿 | US$4.3亿 | US$4.8亿 | -US$34.9亿 | -US$8.6亿 | US$50.6亿 | US$46.9亿 | US$213.2亿 | US$122.7亿 | 3.8% | — | 6.1% | — |
| 2024-12-31 | US$1177.6亿 | US$32.6亿 | US$12.1亿 | US$29.7亿 | US$23.9亿 | US$5.8亿 | US$8.4亿 | US$2.1亿 | US$8.2亿 | US$4.3亿 | US$2.7亿 | -US$29.5亿 | -US$24.9亿 | US$46.9亿 | US$22.2亿 | US$204.4亿 | US$122.6亿 | 2.2% | — | 6.3% | — |
| 2025-12-31 | US$1296.6亿 | US$29.1亿 | US$11.9亿 | US$9.2亿 | US$3.8亿 | US$5.5亿 | US$7亿 | US$2.4亿 | US$1.5亿 | US$4.3亿 | US$4.3亿 | US$22.7亿 | -US$12.2亿 | US$22.2亿 | US$42亿 | US$199亿 | US$129.4亿 | 2.1% | — | 5.6% | — |
Humana Inc. (HUM) trades at 24.3x forward earnings against a peer median of 11.6x. Its EV/EBITDA of 10.2x compares with a peer median of 9.7x. The comparison uses 4 peers: The Cigna Group, Elevance Health Inc., CVS Health Corporation and UnitedHealth Group Incorporated, as of 2026-10-02.
Industry capex-to-revenue stands at 0.9% (0.009) and capex-to-depreciation is 0.81, reflecting an asset-light managed care operational model where reinvestment focuses on digital care management and clinical coordination rather than heavy physical assets. Beyond these benchmark ratios, capacity, supply, and lead-time evidence is unavailable, indicating that the underwriting cycle is demand-led and evidence-limited. Humana capex in FY2025 was $546M on $129.66B revenue (0.42% capex-to-revenue), well below the industry benchmark of 0.9%.6
The bull phase of the managed care cycle is driven by favorable CMS Medicare Advantage benchmark rate increases, medical loss ratio normalization below historical averages, demographic tailwinds from retiring baby boomers, and rapid expansion of value-based primary care networks that capture provider-side cost efficiencies.
The bear phase is characterized by persistent medical inflation, surging inpatient and outpatient procedure volumes among senior cohorts, and restrictive CMS reimbursement updates. Regulatory transitions toward CMS-HCC Version 28 risk-adjustment models and aggressive Star rating downgrades compress underwriting margins below historical norms, while diversified commercial peers compete aggressively for market share, forcing margin-dilutive pricing or volume loss.
Humana exhibits severe cyclical concentration in government-sponsored healthcare, with Insurance representing 96.1% of FY2025 consolidated revenue ($124.56B out of $129.66B,). While CenterWell clinical operations ($1.34B operating income, 5.96% margin) provide partial insulation, Humana lacks the commercial employer insurance diversification of Elevance Health (4.56% operating margin) or the enterprise scale of UnitedHealth Group (7.13% operating margin), leaving corporate profitability uniquely exposed to federal policy shifts.67
Humana trades at $388.36, representing a 46.86% premium to the house Fair value of $264.45 and an implied return of -31.91%. With underwriting margins compressed and regulatory risk elevated, our high-conviction Sell stance mandates zero capital allocation.4
Rigorous risk management mandates avoiding equity commitments where market price trades at an excessive premium to intrinsic value. At $388.36, Humana reflects an aggressive recovery narrative that leaves investors vulnerable to medical cost spikes, CMS audit adjustments, and Star rating bonus losses. Total debt of $12.94B with annual interest of $631M demands disciplined balance sheet monitoring. Investors must enforce a zero-allocation discipline until valuation realigns with fundamental earnings power.
At $388.36 as of October 2, 2026, Humana trades 46.86% above our Fair value of $264.45. With return on invested capital at 6.31% failing to clear the 7.68% cost of capital and total debt at $12.94B, fundamental valuation does not support capital commitment.24
Although first-half 2026 operating cash flow rebounded to $3.22B, Medicare Advantage pricing cycles take multiple years to fully restore underwriting profitability. With 2026 consensus EPS depressed at $9.15, the market has already priced in an aggressive multi-year margin recovery, leaving minimal margin of safety.1
Humana's dividend yield is modest based on a $3.54 annual dividend against a $388.36 share price. Share buybacks were sharply reduced to $151M in FY2025 as cash flow fell to $921M, meaning defensive capital return will remain constrained while debt service and regulatory statutory reserves take precedence.46
Humana is rated Sell with a fundamental Fair value of $264.45, representing an implied return of -31.91% from the report-date price of $388.36 on October 2, 2026. Although management is executing contract repricing and CenterWell generated $1.34B in clinical operating income in FY2025, the market price embeds an overly rapid restoration of Medicare Advantage underwriting margins despite persistent healthcare utilization pressures and regulatory headwinds.47
With total debt standing at $12.94B at year-end FY2025 ($14.74B as of October 2026) and free cash flow contracting to $375M in FY2025, discretionary capital return remains restricted. Investors should liquidate or reduce positions to eliminate exposure to an unfavorable risk-reward skew.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
The Bear scenario captures persistent underwriting compression where senior healthcare utilization remains elevated, CMS reimbursement rate tightening compounds margin pressure, and Star rating bonus reductions materialize. Under these adverse conditions, Insurance segment margins remain pinned near cyclical trough levels and operating cash flow fails to cover structural debt service obligations. This downside pathway would be confirmed by consecutive quarters of medical loss ratio elevation and market share losses to scaled peers.
Consolidated operating income was $2.70B on $129.66B revenue in FY2025 (2.09% margin),. If CMS rate tightening and medical inflation permanently reduce operating margin by 3 percentage points or pin it below 1.5%, OCF would fail to cover debt service of $12.94B.46
Peers with diversified cash flows trade at discounted multiples, including CI at 8.08x forward P/E and CVS at 10.13x,. If regulatory scrutiny permanently derates MA terminal multiples by 20% to 10.4x, fair value falls sharply from the modeled 13.0x.3
Humana's moderate Ke is 8.54% based on a risk-free rate of 5.24% and beta of 0.797. Heightened Medicare Advantage regulatory volatility increasing Ke by 200 bps (+2pp) reduces discounted earnings valuation by 26.5%.2
Signifies persistent medical loss ratio compression and cash conversion deficits that impair ability to service $12.94B total debt.
当前：$921M in FY2025
触发警报：Below $1.50B annually
Falsifies the healthcare services diversification thesis, showing captive clinical operations are shrinking in tandem with health plan membership attrition.
当前：$1.34B in FY2025
触发警报：At or below $1.00B
Signals severe market share loss in individual Medicare Advantage to scaled competitors UNH, CVS, and ELV following benefit design reductions.
当前：25.53% in FY2026 forecast
触发警报：Below 0.0% in FY2027
Confirms structural failure to earn cost of capital, invalidating mid-cycle economic profit recovery assumptions.
当前：6.31% in FY2025
触发警报：Below 5.00% or persistence below WACC of 7.68%
| medium |
| 18 to 36 months |
| Differentiating health plans through exclusive CenterWell clinical care coordination and expanding value-based primary care access to defend core senior retention. |
Under the moderate discount rate, US$59.99 comes from forecast-period earnings and US$252 from the long-term value, totaling US$312.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
The Bull scenario models accelerated margin expansion as Medicare Advantage repricing outpaces medical cost inflation, Star rating quality bonuses are successfully remediated, and CenterWell clinical operations scale rapidly across external payer networks. This optimistic path yields a target of $334.97 with a 20.0% probability, representing an implied return of -13.7% relative to $388.36. Disconfirmation would emerge if medical utilization surges further or if member attrition accelerates in repriced markets.
Quality bonus revenue directly enhances plan pricing flexibility and operating margins across Medicare Advantage contracts.
Clinical service earnings provide non-regulated cash flow and margin defense against pure insurance underwriting volatility.
Cash conversion stability is required to service debt obligations, maintain statutory capital reserves, and eventually restore shareholder distributions.
Sustaining core Medicare Advantage enrollment during contract repricing determines whether market share is preserved against diversified competitors.
| $176.95B |
| $184.91B |
| $192.31B |
| Operating income | $5.21B | $5.39B | $5.66B | $5.92B | $6.15B |
| NOPAT | $3.99B | $4.13B | $4.33B | $4.53B | $4.71B |
| Residual cash after reinvestment policy | $2.99B | $3.09B | $3.25B | $3.40B | $3.53B |
| Revenue growth | 25.5% | 3.5% | 5.0% | 4.5% | 4.0% |
| Operating margin | 3.2% | 3.2% | 3.2% | 3.2% | 3.2% |
| Tax rate | 23.5% | 23.5% | 23.5% | 23.5% | 23.5% |
| Reinvestment rate | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
CenterWell delivered $1.34B in operating profit on $22.47B in revenue in FY2025 (5.96% margin),, providing 49.5% of total corporate operating profit ($2.70B).
Without CenterWell's clinical earnings contribution, consolidated operating margins would have fallen to 1.05%, demonstrating its role as an earnings stabilizer.
Total debt stood at $12.94B at year-end FY2025 ($14.74B as of October 2026) with annual interest charges of $631M.
High fixed debt service requirements limit financial flexibility during downcycles and prevent aggressive balance sheet expansion.
| 利润率 |
|---|
| HUM | Humana Inc. | $46.6B | 24.3x | 0.3x | 10.2x | 6.9% | — |
| CI | The Cigna Group | $71.5B | 8.1x | 0.3x | 7.5x | 16.8% | 4.0% |
| ELV | Elevance Health Inc. | $83.8B | 13.1x | 0.4x | 9.2x | 11.1% | 4.6% |
| CVS | CVS Health Corporation | $110.6B | 10.1x | 0.3x | 10.3x | 6.2% | 3.9% |
| UNH | UnitedHealth Group Incorporated | $333.8B | 16.4x | 0.7x | 14.1x | 14.2% | 7.1% |
| neutral |
| Managed care organizations are expanding ownership of primary care clinics, home health providers, and pharmacy benefit assets to capture clinical delivery margins and coordinate chronic care, though high internal intersegment dependency introduces operational rigidity. |
| Below 0.0% in FY2027 |
| Indicates severe market share loss to peers UNH and CVS; eliminate all residual managed care holdings. |
| Consolidated Operating Cash Flow | Below $1.50B annualized | Confirms chronic cash conversion impairment; maintain Sell stance to avoid liquidity and debt coverage stress. |
